| Cell line name |
Mel 23 |
|---|
| Synonyms |
Melanoma-23 |
|---|
| Accession |
CVCL_0D08 |
|---|
| Resource Identification Initiative |
To cite this cell line use: Mel 23 (RRID:CVCL_0D08) |
|---|
| Comments |
Derived from site: In situ; Oral cavity; UBERON=UBERON_0000167. |
|---|
| Disease |
Canine oral melanoma (NCIt: C185639) |
|---|
| Species of origin |
Canis lupus familiaris (Dog) (Canis familiaris)
(NCBI Taxonomy: 9615) |
|---|
| Sex of cell |
Sex unspecified |
|---|
| Age at sampling |
Age unspecified |
|---|
| Category |
Cancer cell line |
|---|
| Publications | PubMed=19147538; DOI=10.1158/1541-7786.MCR-08-0347; PMCID=PMC2653090
Zhang J., Chen X., Kent M.S., Rodriguez C.O., Chen X.-B.
Establishment of a dog model for the p53 family pathway and identification of a novel isoform of p21 cyclin-dependent kinase inhibitor.
Mol. Cancer Res. 7:67-78(2009) PubMed=19231960; DOI=10.2460/ajvr.70.2.263; PMCID=PMC4169881
Kent M.S., Collins C.J., Ye F.
Activation of the AKT and mammalian target of rapamycin pathways and the inhibitory effects of rapamycin on those pathways in canine malignant melanoma cell lines.
Am. J. Vet. Res. 70:263-269(2009) CLPUB00732
Breit M.N.
Biologic activity of the novel SINE compound KPT-335 against canine melanoma cell lines.
Thesis MSc (2014); Ohio State University; Columbus; USA PubMed=25022346; DOI=10.1186/1746-6148-10-160; PMCID=PMC4105800
Breit M.N., Kisseberth W.C., Bear M.D., Landesman Y., Kashyap T., McCauley D., Kauffman M.G., Shacham S., London C.A.
Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines.
BMC Vet. Res. 10:160.1-160.11(2014) |
|---|
| Cross-references |
|---|
| Encyclopedic resources |
Wikidata; Q54905047
|
|---|
| Entry history |
|---|
| Entry creation | 10-Apr-2015 |
|---|
| Last entry update | 29-Jun-2023 |
|---|
| Version number | 7 |
|---|
